Abstracts tagged "anti-citrullinated protein/peptide antibodies (ACPA)"

Abstract Number: 3019 • 2016 ACR/ARHP Annual Meeting
Sputum Antibodies to Individual Citrullinated Protein/Peptide Antigens Are Elevated in Subjects at-Risk of Future RA and Subjects with Established Disease
Emily Bowers¹, M. Kristen Demoruelle², Michael Weisman³, Jill M. Norris⁴, William H. Robinson⁵, V. Michael Holers² and Kevin D. Deane², ¹Medicine, University of Colorado Denver, Aurora, CO, ²Rheumatology Division, University of Colorado Denver, Aurora, CO, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Epidemiology, Colorado School of Public Health, Aurora, CO, ⁵Stanford University School of Medicine, Stanford, CA
Background/Purpose: Multiple studies demonstrate that ACPAs are elevated in the serum years prior to the onset of seropositive RA during a preclinical period of autoimmunity.…
Abstract Number: 3121 • 2016 ACR/ARHP Annual Meeting
Specific Antibody Subphenotypes in Rheumatoid Arthritis Are Associated with Unique HLA-DRB1 Residues at Position 11
Chikashi Terao^1,2, Boel Brynedal³, Zuomei Chen⁴, Xia Jiang⁴, Helga Westerlind⁴, Monika Hansson⁵, Linda Mathsson-Alm^6,7, Per Johan Jakobsson⁸, Karl Skriner⁹, Guy Serre¹⁰, Johan Rönnelid⁷, Leonid Padyukov⁸, Jane Worthington¹¹, Lars Alfredsson⁴, Lars Klareskog⁸ and Soumya Raychaudhuri^1,2,11, ¹Departments of Genetics and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Program in Medical and Population Genetics, Broad Institute, Boston, MA, ³Section of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Karolinska, Sweden, ⁴Section of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ⁶Thermo Fisher Scientific, Uppsala, Sweden, ⁷Department of Immunology Genetics and Pathology,Uppsala University, Uppsala, Sweden, ⁸Unit of Rheumatology, Department of Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁹Humboldt University of Berlin, Berlin, Germany, ¹⁰Unité Différenciation Épidermique et Autoimmunité Rhumatoïde, Unité Mixte de Recherche, INSERM, Toulouse, France, ¹¹Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Antibody to citrullinated peptides/proteins (ACPA) is specific feature of rheumatoid arthritis (RA) and seen in 50 to 70% of RA patients. Amino acid (AA)…
Abstract Number: 491 • 2016 ACR/ARHP Annual Meeting
Anti-Citrullinated Peptide Antibodies Testing Rate over Time in Newly Diagnosed RA Patients – Data from Three Administrative Claims Databases (2007–2014)
E Alemao, Z Guo and L Burns, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Current clinical guidelines recommend testing for anti-citrullinated protein antibodies (ACPA) at the time of RA diagnosis.1 However, there is a lack of information about…
Abstract Number: 496 • 2016 ACR/ARHP Annual Meeting
Impact of Anti-Citrullinated Protein Antibody and/or Rheumatoid Factor on Rheumatoid Arthritis Manifestations and Outcomes
Ee Tzun Koh¹, Angela Marie Chan¹, Wei Qiang See², Wenwei Xiang², Khai Pang Leong¹ and Tan Tock Seng Rheumatoid Arthritis Study Group, ¹Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore, ²Clinical Research and Innovation Office, Tan Tock Seng Hospital, Singapore, Singapore
Background/Purpose: RA Patients with anti-citrullinated protein antibody (ACPA) or rheumatoid factor (RF) are known to have worse clinical outcomes compared to seronegative patients. To determine…
Abstract Number: 578 • 2016 ACR/ARHP Annual Meeting
Do Specific Anti-Citrullinated Antibodies Predict Different Phenotype of Rheumatoid Arthritis?
Mikael Brink¹, Monika Hansson², Linda Mathsson-Alm^3,4, Johan Rönnelid⁵, Karl Skriner⁶, Guy Serre⁷, Lars Klareskog² and Solbritt Rantapää-Dahlqvist¹, ¹Rheumatology, Umeå University, Umeå, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³ThermoFisher Scientific, Uppsala, Sweden, Uppsala, Sweden, ⁴Thermo Fisher Scientific, Uppsala, Sweden, ⁵Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁶Humboldt University of Berlin, Berlin, Germany, ⁷Unité Différenciation Épidermique et Autoimmunité Rhumatoïde, Unité Mixte de Recherche, INSERM, Toulouse, France
Background/Purpose: Antibodies against cyclic citrullinated peptides (anti-CCP) have been suggested to identify a more severe phenotype of rheumatoid arthritis. In this study we have analysed…
Abstract Number: 495 • 2015 ACR/ARHP Annual Meeting
Prognostic Significance of Residual Inflammation and Autoantibodies for Disease Relapse upon DMARD Suspension in Patients with Rheumatoid Arthritis in Sustained Remission after DAS-Driven Therapy
Antonio Manzo¹, Serena Bugatti¹, Francesca Benaglio¹, Garifallia Sakellariou¹, Barbara Vitolo¹, Carlomaurizio Montecucco¹ and Roberto Caporali², ¹Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy, ²Division of Rheumatology, Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy
Background/Purpose: Early diagnosis and treat-to-target strategies with conventional DMARDs in rheumatoid arthritis (RA) have allowed the achievement of remission in a significant percentage of the…
Abstract Number: 560 • 2015 ACR/ARHP Annual Meeting
Impact of Anti-Citrullinated Protein Antibody Status and Response to Abatacept
Leslie Harrold^1,2, KK Gandhi³, H Litman⁴, S Kelly³, YF Li⁵, E Alemao³, S Deveikis⁴ and J Greenberg^1,6, ¹Corrona, LLC, Southborough, MA, ²Dept of Medicine, University of Massachusetts Medical School, Worcester, MA, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Corrona, LLC., Southborough, MA, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶NYU School of Medicine, New York, NY
Background/Purpose: Response to therapies may vary based on anti-citrullinated protein antibodies (ACPA) status. We compared treatment response to abatacept in ACPA-positive versus -negative RA patients…
Abstract Number: 1207 • 2015 ACR/ARHP Annual Meeting
Predictive Utility of Anti- Citrullinated Peptide Antibodies and Rheumatoid Factor – a Retrospective Dataanalysis
Miriam Gärtner, Mathias Schneeweiss, Josef S. Smolen and Klaus Machold, Department of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Antibody profiling encompassing rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA) supports diagnosis in patients with Rheumatoid arthritis (RA). However, RF and ACPA are…
Abstract Number: 1217 • 2015 ACR/ARHP Annual Meeting
Phenome-Wide Association Study of Novel Anti-Citrullinated Peptide Antibodies in Rheumatoid Arthritis
Katherine Liao¹, Jeffrey A. Sparks¹, Boris Hejblum², I-Hsin Kuo¹, Jing Cui¹, Lauren J. Lahey³, Andrew Cagan⁴, Vivian Gainer⁴, Weidong Liu⁵, Tony Cai⁶, Jeremy Sokolove⁷ and Tianxi Cai², ¹Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA, ²Biostatistics, Harvard School of Public Health, Boston, MA, ³Medicine, VA Palo Alto HealthCare System and Stanford University, Palo Alto, CA, ⁴Research Computing, Partners HealthCare, Charlestown, MA, ⁵Institute of Natural Sciences, Shanghai Jiao Tong University, Shanghai, China, ⁶Statistics, University of Pennsylvania, Philadelphia, PA, ⁷Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA
Background/Purpose: RA patients develop autoantibodies against a spectrum of antigens. However, the clinical significance of these autoantibodies after RA diagnosis is unclear. The Phenome-Wide Association…
Abstract Number: 1615 • 2015 ACR/ARHP Annual Meeting
Lack of Replication of the Association Between Anti-Citrullinated Fibrinogen and Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis
Ariana Montes¹, Alfonso Corrales², Manuel Calaza³, Raquel López-Mejías⁴, José Antonio Parra⁵, Miguel Angel Gonzalez-Gay⁶ and Antonio Gonzalez⁷, ¹Laboratorio Investigacion 10 and Rheumatology Unit, Instituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ³Laboratorio Investigacion 10 and Rheumatology Unit. Instituto Investigacion Sanitaria.Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ⁴Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ⁵Radiology Division, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ⁷Instituto Investigacion Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
Background/Purpose: A recent study has suggested that the excess cardiovascular (CV) risk observed in patients with rheumatoid arthritis (RA) could be partially explained by immune-complexes…
Abstract Number: 1617 • 2015 ACR/ARHP Annual Meeting
Evidence for Citrullinated Inhibitor of DNA Binding 1 (Id1) As a Novel Autoantigen Candidate in Rheumatoid Arthritis
Ray A. Ohara¹, Gautam Edhayan¹, W. Alexander Stinson², Phillip L. Campbell¹, Henriette A. Remmer³, M. Asif Amin¹, David A. Fox¹ and Jeffrey H. Ruth¹, ¹Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ³Biomedical Research Core Facilities, Proteomics & Peptide Synthesis Core, University of Michigan Medical School, Ann Arbor, MI
Background/Purpose: Inhibitor of DNA-binding 1 (Id1) is a nuclear transcription factor actively transcribed in endothelial progenitor cells and in cells that exhibit hyperproliferative responses such…
Abstract Number: 2464 • 2015 ACR/ARHP Annual Meeting
Characterization of the Serum Anti-Citrullinated Protein Antibody Profile in Juvenile Idiopathic Arthritis: Association with Oral Health
Sampath Prahalad¹, Lauren J. Lahey², Geoffrey M. Thiele³, Lori Ponder¹, Sheila T. Angeles-Han¹, Lauren Lange⁴, Aimee O. Hersh⁵, Mina Rohani-Pichavant¹, Se Ryeong Jang¹, Larry B. Vogler¹, Patricia Vega-Fernandez¹, Kelly A. Rouster-Stevens¹, John F. Bohnsack⁶, Ted R. Mikuls⁷ and Jeremy Sokolove⁸, ¹Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, ²Medicine, VA Palo Alto HealthCare System and Stanford University, Palo Alto, CA, ³Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁴Pediatrics, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁵Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, ⁶Pediatrics, University of Utah Health Sciences Center, Salt Lake City, UT, ⁷Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁸Stanford University, Palo Alto, CA
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic childhood arthropathy. Most children with JIA phenotypically differ from adults with rheumatoid arthritis (RA) although…
Abstract Number: 2551 • 2015 ACR/ARHP Annual Meeting
Antibodies to Malondialdehyde-Acetaldhyde Adducts Are Increased in the Serum of Mice Following Infection with P. Gingivalis and/or Injection of Citrullinated Mouse Type II Collagen: a Model of Human Disease Response
Geoffrey M. Thiele⁴, Einstein Juma¹, Roxanne Haslam¹, Michael J. Duryee², Anand Dusad³, Carlos D. Hunter², James R. O'Dell⁴, Lynell W. Klassen⁴, Ted R. Mikuls⁴ and Geoffrey M. Thiele⁴, ¹University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with RA complicated by periodontal disease (PD) have been shown to have higher anti-citrullinated protein antibody (ACPA) levels, which have also become predictive…
Abstract Number: 3074 • 2015 ACR/ARHP Annual Meeting
The Shared Rheumatoid Arthritis HLA-DRB1 Susceptibility Epitope Shapes the Molecular Orientation of Citrulline and the Autoreactive T Cell Receptor Repertoire
Jurgen van Heemst¹, Stephen Scally², Soi Cheng Law³, Diane van der Woude⁴, Carol Hitchon⁵, David B. Robinson⁶, T. W. J. Huizinga⁷, Hugh H Reid⁸, René E. M. Toes⁷, Hani El-Gabalawy⁹, Jamie Rossjohn¹⁰ and Ranjeny Thomas¹¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Monash University, Melbourne, Australia, ³The University of Queensland Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Australia, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, ⁷Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁸Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Melbourne, Australia, ⁹University of Manitoba Arthritis Center, Winnipeg, MB, Canada, ¹⁰Institute of Infection and Immunity, Cardiff University, School of Medicine, Heath Park, Cardiff, England, ¹¹Translational Research Institute, The University of Queensland Diamantina Institute, Brisbane, Australia
Background/Purpose: Large-scale genomic studies have identified many genetic associations with autoimmune diseases, but the precise pathogenetic mechanisms by which the associated genes impact disease susceptibility…
Abstract Number: 2502 • 2014 ACR/ARHP Annual Meeting
Ten Year Follow-up Results of Four Dynamic Treat to Target Strategies in Patients with ACPA Negative Rheumatoid Arthritis
I.M. Markusse¹, G. Akdemir², L. Dirven², M. van den Broek², K.H. Han³, H.K Ronday⁴, P.J.S.M. Kerstens⁵, W.F. Lems^6,7, T.W.J. Huizinga² and C.F. Allaart², ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, MCRZ hospital, Rotterdam, Netherlands, ⁴Rheumatology, Haga Hospital, The Hague, Netherlands, ⁵Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁶Rheumatology, VU Medical Center, Amsterdam, Netherlands, ⁷Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands
Background/Purpose: To determine the optimal treatment strategy in patients with anti-citrullinated protein antibodies (ACPA) negative (‒) rheumatoid arthritis (RA), as it has been suggested that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].